Investorideas.com - Agora Financial "A Tale of Two Americas" Conference Gives Investors a Radical and Brilliant Insight into Investing

Investorideas.com - Agora Financial "A Tale of Two Americas" Conference Gives Investors a Radical and Brilliant Insight into Investing

Agora Financial “A Tale of Two Americas “ Conference Gives Investors a Radical and Brilliant Insight into Investing




New York, NY- Point Roberts WA–July 26, 2013 – (www.investorideas.com newswire,) Investorideas.com, an investor research portal featuring global investing ideas for independent investors issues a special feature on the Agora Financial Investment Symposium held this week in Vancouver at the Fairmont Vancouver, closing up today at 4:00. For investors looking for unique opportunities in both private companies and publicly traded companies, this event entitled, A Tale of Two Americas- Seeking Opportunity at the Crossroads of Great Energy Revolution, Radical New Technologies and the Crushing Debt Crisis, does just that.



For investors tired of mainstream investment commentary from CNBC and Yahoo Finance, this conference featured exhibitors and speakers that are introducing ideas, services and technologies that are new, groundbreaking and sometimes controversial.



In terms of technology and ideas that most investors are not aware of, Chris Anderson, former editor of Wired, shared a vision of his company, 3D Robotics. In his presentation, The New Industrial Revolution, he talks about changing the face of manufacturing forever if 3d Printing is adopted into mainstream. 3D printing may be possible to change the way inventors and entrepreneurs bring new products to market in a very short time and in a cost effective manner. It truly takes the mantra of if you can think it you can create it to a whole new level.



Another example was a newly listed TSX agriculture stock, the first of its kind in the sector, Input Capital Corp (TSX: INP.V). Input is the world's first agriculture commodity streaming company. Using its innovative, proprietary agriculture streaming process, Input makes an upfront payment to the owner/operators of grain and oilseed farms in Western Canada in exchange for the purchase of a portion of their future production at a fixed price per tonne for the life of the streaming contract. This long-term working capital enables farmers to unlock the yield potential of their crops by optimizing their inputs and precision farming practices. Input currently has a focus on canola in Saskatchewan, Alberta and Manitoba. The company follows the model set in the mining industry by companies like Silver Wheaton, the largest precious metal streaming company in the world.



full article :http://www.investorideas.com/news/2013/main/07264.asp

Stem Cell Stock Alert: BioRestorative Therapies (OTCBB: BRTX) CEO Mark Weinreb Interviewed by The Life Sciences Report

SAN FRANCISCO, CA - July 25, 2013 (Investorideas.com Newswire) "Millions of people suffer back pain caused by herniated and bulging disc disease. When conventional medical therapies fail, they often resort to surgery for relief, a costly and time-consuming solution for both patients and the medical system. In this interview with The Life Sciences Report, Mark Weinreb, president, CEO and chairman of BioRestorative Therapies Inc. (OTCQB: BRTX), describes how his company's cell therapy process could keep disc disease treatment out of the operating theater.

The Life Sciences Report: Mark, what disease indication are you exactly going after for patients suffering with back pain?
Mark Weinreb: We have developed a novel cellular therapy and therapeutic delivery device for the treatment of bulging and herniated disc disease. We believe we can effectively and safely treat patients using a nonsurgical, minimally invasive procedure that can be performed routinely in a physician's office. This technology could effectively bridge the gap between noninvasive and surgical back procedures. There are at least one million people, annually, in the U.S. who could benefit from this type of procedure with the promise of avoiding surgery. We elected to pursue this market because of the early success we have seen in several patients who have received this treatment.
TLSR: Can you very briefly describe the technology?"
Continue reading this interview with Mark Weinreb: "BioRestorative Therapies Inc. Develops Plug-and-Play Therapy for Bulging and Herniated Disc Disease."
Read more about cell therapy and BioRestorative Therapies Inc. in The Life Sciences Report's in-depth interview with Jason Kolbert of Maxim Group: "Is Cell Therapy the 'Future of Medicine'?"
About Streetwise Reports - The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends. This valuable insight is integrated with in-depth company information, summaries from the latest research and news that will help you make smart investment decisions.
Contact:
Streetwise Reports, LLC - The Life Sciences Report
Brandon Fung
Tel: 707-981-8107
Disclaimer /Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk.
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: BioRestorative has compensated Investoridea for a six month news program ( five thousand ) to be published on Investorideas.com newswire and syndication and social media partners.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Solar Industry to grow to $155 billion in 2018; U.S. Photovoltaic Manufacturing Consortium Aims to help make CIGS thin films a significant part of that solar success

Point Roberts, WA - July 25, 2013 (Investorideas.com renewable energy stocks newswire) Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including renewable energy stocks, reports on the future of the solar sector and in particular, CIGS solar and the related solar stocks.

Lux Research says the solar photovoltaic (PV) market is poised to rise from the ashes of its 2011 crisis to grow to $155 billion in 2018, as market forces engineer a turnaround to a healthy 10.5% compound annual growth rate (CAGR.
They went on to say, "In the most likely scenario, the PV market will grow at a modest clip to 35 GW in 2013 before rapidly ramping up to 61.7 GW in 2018."
The U.S. Photovoltaic Manufacturing Consortium (PVMC) recently said in a press release, "Photovoltaics and especially thin-film PV are again at a tipping point," said Larry Kazmerski, co-chair of the U.S. CIGS PV Roadmap. "We want PV to be a substantial part of the world's energy portfolio and our efforts with this roadmap are aimed to help make CIGS thin films a significant part of that solar success."
CIGS solar stocks to watch include XsunX , Inc. (OTCQB: XSNX) , Ascent Solar Technologies, Inc. (NASDAQ:ASTI), Solar Frontier subsidiary of Showa Shell Sekiyu K.K. (TYO: 5002) and TSMC Solar, a wholly-owned subsidiary of Taiwan Semiconductor Manufacturing, Inc. (NYSE:TSM).
XsunX , Inc. (OTCQB: XSNX) closed up over 21% on just over 4 Million shares as of the close on Wednesday, gaining some of the ground it had lost in recent sessions. XsunX says its CIGSolar technology focuses on the mass production of thin-film CIGS solar cells utilizing a proprietary multi-area thermal deposition process to minimize processing defects to create highly uniform CIGS films. The manufacturing systems are modular and represent a new breed of CIGS manufacturing technology that can be deployed in various production configurations to produce CIGSolar cells. The potential impact and opportunity is to offer commercially viable replacements to existing incumbent poly-crystalline silicon technology, lowering the overall cost of PV energy.
TSMC Solar said this week that its new target for CIGS module conversion efficiency is now set for 17 percent and utility expansion of 50 percent by 2014. In June the company reported confirmation by TUV SUD that its latest commercial-sized (1.09 m2) CIGS champion module has achieved 15.7% module total area efficiency. The new champion module improves on TSMC Solar's previous 15.1% world record set in January this year. The module was produced using the current manufacturing equipment and materials at the company's manufacturing facility in Taichung, Taiwan. The stock moved up on the day of the new targets announced.
Ascent Solar Technologies, Inc. (NASDAQ:ASTI) said earlier this week it will debut the newest additions to its EnerPlex KickrTM Series as well as introduce an exciting new line of EnerPlexTM products to be showcased at the Outdoor Retailer Summer show in Salt Lake City July 31st through August 3rd. Small enough to be attached to a belt loop yet powerful enough to make sure devices always have a charge, the Kickr line of personal solar chargers is uniquely enabled by the rugged, lightweight and flexible form factor of Ascent's CIGS solar cells.
The stock has made some big moves just over the last month and closed up marginally again on the close of Wednesday's session.
Among Lux Research findings:
U.S., China, Japan, and India will take over where Germany and Italy left off. With an 18% CAGR to 10.8 GW of installations in 2018, the United States will emerge the world's second-largest market. But China will leapfrog it, growing over 15% annually to 12.4 GW in 2018.
Utility-scale installations to grow the fastest; commercial the largest. Utility-scale solar, the smallest segment in 2012 at 8.6 GW, will grow the fastest to 19.9 GW in 2018 as developing markets turn to PV. Globally, commercial applications reign supreme as markets like the U.S. and Japan move to large rooftop installations.
Opportunities abound for cheap IP. Struggling start-ups present opportunities to acquire intellectual property at record low prices. A case in point: Hanergy acquired Miasolé - which in 2012 announced the leading CIGS module efficiency at 15.5% - for only $30 million after investors had pumped $500 million into the firm.
About InvestorIdeas.com: Big ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free solar stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by XSNX for news distribution averaging fifteen hundred per month
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
800-665-0411 - Source - www.Investorideas.com

Investorideas.com Q&A with Juan Carlos Gonzalez, Foreign Investment Vice-President at Proexport Colombia

Point Roberts WA, New York, NY - July 25, 2013 (www.investorideas.com newswire) Investorideas.com, an investor research portal specializing in sector research for global investors issues an exclusive interview with Juan Carlos Gonzalez, the Foreign Investment Vice-President at Proexport, Colombia, a National Agency for the promotion of FDI, non-traditional exports and international tourism. The interview gives insight into the past, present and future relationship between Colombia and Canada and how the mindset of a country can change its destiny.

With a population of 47 Million people and a demographic of 55% being younger than 30, his closing comment was possibly the most significant in the interview.
When asked what has changed the most in Colombia over the past ten years and what the biggest driving force is, he told Investorideas.com that it was a change of mindset. “Colombians started to believe that their future would be better than their past . Ten years ago a young person's biggest goal was to leave Colombia, now it is to start a business. “
If Colombia could bottle that optimism and entrepreneurial spirit, it could possibly become its biggest export .
The following is a summary of the discussion that took place July 19 th.
Q: Investorideas.com
Before we discuss the future of the trade relationship between Canada and Colombia, can you give us a glimpse of what has happened since the Canada/ Colombia Free Trade Agreement became effective in 2011?
A: Juan Carlos Gonzalez, Foreign Investment Vice-President at Proexport Colombia
Canada was the first G7 country to open up new markets in Colombia . It was a big leap not just for Colombia but also for neighboring markets. One of the biggest impacts was the growth in tourism and how it opened up the eyes of Canadians to a new Colombia.
Over the past two years both countries have learned about each others markets. Proexport has actively promoted the opportunities that exist between the two countries and has expanded its presence in Canada, with offices in Vancouver, Toronto and Montreal .
More Colombian countries are exporting to Canada, but the true picture is not all reflected in just the numbers. It's more about the mutual education of opportunities. Colombians did not know a lot about Canada prior to the agreement and Canadians needed to learn more about the potential role of Colombia in its future . One of the key points we try to educate foreign business on is that the country is split into very different regions that each represent their own unique opportunities .
The FTA created a venue that allows for a flow of business but education is essential to show business on both sides how to take advantage of it.
We are now seeing opportunities expand beyond traditional markets of oil and gas, mining and coffee.
Q: Investorideas.com
How much of a role does Canada play in Colombia's economy ?
A: Juan Carlos Gonzalez, Foreign Investment Vice-President at Proexport Colombia
Since August 2011- May 2013, a significant number of Colombian companies exported to Canada for the first time . Stats show 140 new Colombian companies have exported their products to Canada with 66 new products
There has been a lot of growth in non traditional exports including flowers, textiles, cosmetics and auto parts.
According to Stats Canada , Colombian exports to Canada reached US$ 218, 5 million between January and April 2013, and the subsectors with greater participation include those that have contributed traditionally to trade between the two countries. Coal and Petroleum (39%), Coffee (23%), Flowers (14%), Banana and other fruits (10%). These 4 represent 85% of Colombian exports to Canada.
When asked about progress in global markets, Juan Carlos Gonzalez noted that Colombia is seeing record growth. Ten years ago global exports were 11 Billion and last year it rose to 60 Billion. Another significant indicator is the inflow of foreign investment over the past 10 years. Colombia is ranked 3 rd after Chile and Brazil for investment into South American countries. In 2012, Colombia received over $15 billion of Foreign Direct Investment.
Tourism is also a growing market, expanding from just over 300,000 visitors then years ago to over 3 Million now.
Q: Investorideas.com
Can you discuss Colombia's investor protection policy and its global ranking ?
A: Juan Carlos Gonzalez, Foreign Investment Vice-President at Proexport Colombia
Colombia has been very stable and has not defaulted on its debt. Colombia takes all investment very seriously and is responsible to its investors. According to the World Bank, its global ranking we are number 6, while Canada is number 4 in the world. Their ranking measures the strength of minority shareholder protections against misuse of corporate assets by directors for their personal gain.
The World Bank also notes that Colombia is the third most business-friendly and the leading reforming country in Latin America.
Q: Investorideas.com
How tax friendly is Colombia to the business community?
A: Juan Carlos Gonzalez, Foreign Investment Vice-President at Proexport Colombia
The corporate tax rate is 33% but Colombia is very proactive and has created free trade regions with tax rates of 15%.
As part of the government's effort to create jobs, there are also incentives to start business in certain sectors. Additionally they have lowered payroll taxes based on certain tax reforms passed last year. Payroll taxes have been lowered from 50% to 25- 30%.
Q: Investorideas.com
What industry sectors are untapped for new business between Colombia and Canada?
A: Juan Carlos Gonzalez, Foreign Investment Vice-President at Proexport Colombia
Colombia has a sizeable growing market of over 47 Million people, currently the second largest Spanish speaking country in the world after Mexico.
There is a growing dynamic middle class economy that creates opportunity on many fronts, and in particular consumer products. Colombia is seeing a lot of retail and consumer markets opening up. Not only do the companies get to serve Colombia consumers, but also surrounding countries.
Some examples of untapped opportunities include service providers for the oil and gas and mining sectors. There is a great opportunity to serve the resource industry and identify areas where they don't have technology to meet the needs; for example, environmental services or pipeline services.
Another key area to look at is the services sector. There is a growing population and talent pool to capitalize on. Many companies are coming into Colombia and setting up customer service centers.
Canada 's animation industry has come to Colombia looking for expertise in the digital sector as well as telecom companies have set up operations in Colombia to serve Latin American markets.
Colombia also has a gap in infrastructure, including transportation, housing, construction and the materials sector.
There is also a growing market for cleantech and renewable energy technologies. Foreign companies have come into Colombia with waste management and waste to energy technologies.
Juan Carlos also made clear that small and medium businesses looking to start operations or trade with Colombia should contact Proexport and make use of their resources. They can help business create a tailor made plan specific to their sector. Colombia is looking for innovation and partners and small business is always known to bring innovation to the forefront.
The Colombian government is making it easier for new business to get Visas, to encourage and promote innovation and R&D.
So for business leaders looking for new opportunities and a new frontier - all roads lead to Colombia …
Interview by D. Van Zant Investorideas.com
Bio /Juan Carlos Gonzalez Foreign Investment Vice-President at Proexport
He has been in charge of designing and implementing Colombia´s foreign investment promotion strategy as the country has become one of the top
recipients of FDI in Latin America. Proexport was ranked by the World Bank (FIAS) in 2009 among the top 25 Investment Promotion Agencies in the world
out of 213 agencies assessed by the quality of the information and services provided to prospective investors. Between January 2009 and June
2010, 98 new projects with expected investments of over US$1.5 billion were initiated in Colombia by foreign investors supported by Proexport.
Previously, Mr. Gonzalez was Economic and Trade Attaché at the Colombian Embassy in Japan, Vice-President at the Invest in Colombia Corporation
-COINVERTIR- , Director for International Affairs at the National Directorate of Taxes and Customs, and Adviser to the Minister of Foreign Affairs.
Mr. Gonzalez did his undergraduate studies in Economics at Universidad de los Andes ( Bogota), Lewis and Clark College ( Portland, Oregon) and Hokusei
Gakuen University ( Sapporo, Japan). He holds a Master´s degree in International Studies from the University of Washington ( Seattle), and an MBA from the Melbourne Business School ( Australia).
He is fluent in English and Japanese and has working level proficiency in French and Portuguese.
Proexport Colombia
http://www.proexport.com.co/en
Proexport provides business opportunities, clear information on requirements, strategies for expanding services and goods at an international level, participation in business fairs and assistance by experts for investors, exporters, and professionals that wish to come closer to their dreams.
About InvestorIdeas.com:
www.InvestorIdeas.com is a global leader in investor sector research, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy and beverage stocks.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities.
800-665-0411 - Source - www.Investorideas.com

Mining Stock Alert: SilverCrest (TSX.V: SVL) (NYSE MKT: SVLC) Announces Santa Elena Expansion Pre-Feasibility Study; Base Case NPV @ $243.7 Million and 88% IRR 8 Years of Mine Life Added

Vancouver, British Columbia - July 25, 2013 (Investorideas.com Mining Stocks Newswire) SilverCrest Mines Inc. (TSX.V:SVL) ( NYSE MKT: SVLC) is pleased to announce that it has filed its NI 43-101 Technical Report entitled “Santa Elena Expansion Pre-Feasibility Study and Open Pit Reserve Update” for its operating mine located in Sonora, Mexico. Summaries of the revised Life of Mine Plan (LOMP), operating costs, capital costs and Expansion project economics are presented in tables below. All dollar amounts are expressed in U.S. dollars unless otherwise specified. The effective date of this Technical Report is April 30, 2013.

The economic analyses use Base Case metal prices of $1450/ounces of gold and $28/ounces of silver (3 year average historical trend). On this basis, the following economic highlights for an additional 8 years of mine life beginning in January 2014 are;

• Total operating revenue of $684.9 million from estimated sales of 12.11 million ounces of silver and 262,739 ounces of gold.
• Total operating costs of $282.2 million with estimated cash operating costs averaging US$11/ounce AgEQ for mine life with lower costs in initial years.
• Total capital costs of $87.8 million including contingency but excluding sunk costs up to April 30, 2013.
• Total pre-tax cash flow of $302.5 million including estimated cost deductions for closure (US$ 5 million) and working capital (US$1.8 million).
• Base Case pre-tax NPV (DCF @ 5%) of $243.7 million including 2013 estimated net cash flow of $20 million at $1250 /ounce of gold and $19.50/ounce of silver after effective date of April 30, 2013 .
• IRR of 88% based on incremental project economics excluding sunk costs up to April 30, 2013.
• Payback period of 1 year.
• AgEQ based on a ratio of 70:1 which includes average metallurgical recoveries of 92% Au and 67.5% Ag for all milling ores.

Metal price sensitivities were completed including $1250/oz Au and $19.50/oz Ag which showed a pre-tax NPV (DCF @ 5%) of $128.7M (including 2013 est. net cash flow) and an IRR of 49%.
Updated Mineral Reserve and Resource estimations for Santa Elena Mine were announced in a news release dated May 29, 2013 which showed Probable Reserves (underground, open pit and leach pad) at an estimated 8.2 million tonnes grading 74.9 gpt Ag and 1.24 gpt Au containing 19.7 million ounces of silver and 327,430 ounces of gold. Updated Indicated Resources (exclusive of Probable Reserves) were estimated at 2.1 million tonnes grading 114.9 gpt Ag and 1.69 gpt Au containing 7.9 million ounce of silver and 116,000 ounces of gold. Only Mineral Reserves were used in the PFS mine plan, schedule and economic analysis. Mineralization at Santa Elena is open in most directions with excellent potential to further increase resources and reserves for increased production and mine life.
J. Scott Drever, Chairman and CEO commented: “We are extremely pleased with the results of the PFS which confirms our expectations that the transition from our open pit heap leach operation to a conventional mill and underground operation will represent a very attractive project with robust economics even at current reduced metal prices. The 8 year mine life will give SilverCrest a strong corporate cash flow providing a solid foundation for continued systematic and aggressive growth. We look forward to a banner year in 2014 with the commissioning of the new processing facility in the first quarter and the significant expansion of our annual metals production at Santa Elena.”
EXPANSION LIFE OF MINE PLAN
The Santa Elena mine life with updated Reserves is scheduled for an additional 8 years at nominal milling rate of 3,000 tonnes per day. The mine schedule is based on mining long hole stopes (69% by reserve volume) early in the mine life at attractive lower costs with higher cost cut and fill stopes (31% by reserve volume) being mined towards the end of the mine schedule. The average width of proposed stopes is 13.4 metres which is advantageous for lower cost bulk mining methods. SilverCrest envisions a blending strategy during operations at variable rates for mill feed to achieve optimum throughput. A summary of the mine and production schedule is presented below with proposed initial blending strategy.

1 Included for Reserve declaration purposes only but not included in economic analyses for the Expansion

This plan excludes an estimated 750,000 tonnes of heap leach spent ore which will be placed on the pad in 2013 and accounted for in early 2014 as additional material for reprocessing during the mine life.
EXPANSION OPERATING COSTS
The operating cost estimates stated below were compiled using Santa Elena mine site operating experience, SilverCrest financial and operational reports, recent contractor quotes, other local producing mines and industry estimations in Mexico to a Pre-Feasibility level.

1 Long hole stopes are 69% of designed stopes by volume and cut & fill stopes are 31% of designed stopes by reserve volume. Excludes ore development costs. $/t inclusive of ore dev. Is estimated at $21 to $48.
2 Processing includes crushing, milling, site refining and dry stack tailings disposal.
3 Estimated based on current operations and may vary on an annual basis.

EXPANSION CAPITAL COSTS
The capital cost estimates stated below were compiled using Santa Elena mine site experience, recent contractor quotes, other local producing mines and industry estimations in Mexico to a Pre-Feasibility level.
EXPANSION ECONOMIC ANALYSIS
Pre-Feasibility level economic analyses were completed for both pre-tax and post-tax. Base Case pre-tax results are stated as follows;

1 Operating cost per AgEQ oz. sold varies between $9.6 and $12.6 over the life of mine
2 Excludes sunk costs, up to April 30, 2013, closure costs and working capital
3 Includes deductions of $5 million for closure costs and $1.8 million for working capital
4 Includes 2013 estimated net cash flow after effective date of April 30, 2013
5 The IRR presented here do not reflect total project economics but reflect incremental project economics as they do not include sunk costs for the Santa Elena expansion prior to April 30 2013

The economic analyses consider SilverCrest delivering a remaining 31,000 ounces of gold (2014 and beyond) to Sandstorm Gold Ltd. (Sandstorm) at a price of $350/oz under the Sandstorm Purchase Agreement executed on May14th, 2009. It does not include the option held by Sandstorm to participate in the future underground mine production which would require payment by Sandstorm of 20% (pro-rata of gold) of the capital costs with a subsequent increase of gold price for 20% of produced ounces to $450/oz Au. Sandstorm may elect to participate in the expansion, once SilverCrest provides a preliminary technical report that includes amongst other items; the required capital costs associated with the transition from open pit heap leaching to a conventional mill facility and underground mine.
EXPANSION PRE-FEASIBILTY RECOMMENDATIONS
Further optimization of the mine schedule is warranted to investigate grade optimization versus stoping costs (long hole or cut and fill), potential to expand and accelerate increased underground production with a second ramp for the bottom of the pit and expand milling capacity. These optimizations will be addressed in detail after successfully announcing commercial production for the new mill facility in 2014. Mineralization at Santa Elena is open in most directions with excellent potential to further increase resources and reserves for increased production and mine life. Further infill and expansion drilling is recommended.
The Qualified Persons for this Technical Report and who have reviewed and approved the contents of this news release are N. Eric Fier, CPG, P.Eng., President and Chief Operating Officer for the Company, James Barr., P.Geo., Mike Tansey, P.Eng. and Carlos Chaparro, P.Eng. from the consulting firm of EBA, a Tetra Tech Company, and John Fox, P.Eng. of Laurion Consulting Inc.
SilverCrest Mines Inc. (TSX VENTURE:SVL)(NYSE MKT:SVLC) is a Canadian precious metals producer headquartered in Vancouver, BC. SilverCrest's flagship property is the 100%-owned Santa Elena Mine, located 150 km northeast of Hermosillo, near Banamichi in the State of Sonora, México. The mine is a high-grade, epithermal silver and gold producer, with an estimated life of mine cash cost of US$8 per ounce of silver equivalent (55:1 Ag: Au). SilverCrest anticipates that the 2,500 tonnes per day open pit heap leach facility at the Santa Elena mine should recover approximately 625,000 ounces of silver and 33,000 ounces of gold in 2013. Major expansion and construction of a 3000 tonnes per day conventional mill facility is underway to significantly increase metals production at the Santa Elena Mine (open pit and underground) by 2014. Exploration programs continue to make new discoveries at Santa Elena and also have rapidly advanced the definition of a large polymetallic deposit at the La Joya property in Durango State with stated resources nearing 200 million ounces of Ag equivalent.
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" within the meaning of Canadian securities legislation and the United States Securities Litigation Reform Act of 1995. Such forward-looking statements concern the Company's anticipated results and developments in the Company's operations in future periods, planned exploration and development of its properties, plans related to its business and other matters that may occur in the future. These statements relate to analyses and other information that are based on expectations of future performance, including silver and gold production and planned work programs. Statements concerning reserves and mineral resource estimates may also constitute forward-looking statements to the extent that they involve estimates of the mineralization that will be encountered if the property is developed and, in the case of mineral reserves, such statements reflect the conclusion based on certain assumptions that the mineral deposit can be economically exploited.
Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements, including, without limitation: risks related to precious and base metal price fluctuations; risks related to fluctuations in the currency markets (particularly the Mexican peso, Canadian dollar and United States dollar); risks related to the inherently dangerous activity of mining, including conditions or events beyond our control, and operating or technical difficulties in mineral exploration, development and mining activities; uncertainty in the Company's ability to raise financing and fund the exploration and development of its mineral properties; uncertainty as to actual capital costs, operating costs, production and economic returns, and uncertainty that development activities will result in profitable mining operations; risks related to reserves and mineral resource figures being estimates based on interpretations and assumptions which may result in less mineral production under actual conditions than is currently estimated and to diminishing quantities or grades of mineral reserves as properties are mined; risks related to governmental regulations and obtaining necessary licenses and permits; risks related to the business being subject to environmental laws and regulations which may increase costs of doing business and restrict our operations; risks related to mineral properties being subject to prior unregistered agreements, transfers, or claims and other defects in title; risks relating to inadequate insurance or inability to obtain insurance; risks related to potential litigation; risks related to the global economy; risks related to the Company's status as a foreign private issuer in the United States; risks related to all of the Company's properties being located in Mexico and El Salvador, including political, economic, social and regulatory instability; and risks related to officers and directors becoming associated with other natural resource companies which may give rise to conflicts of interests. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the forward-looking statements. The Company's forward-looking statements are based on beliefs, expectations and opinions of management on the date the statements are made. For the reasons set forth above, investors should not place undue reliance on forward-looking statements.
The information provided in this news release is not intended to be a comprehensive review of all matters and developments concerning the Company. It should be read in conjunction with all other disclosure documents of the Company. The information contained herein is not a substitute for detailed investigation or analysis. No securities commission or regulatory authority has reviewed the accuracy or adequacy of the information presented.
J. Scott Drever
Chairman and CEO
SILVERCREST MINES INC.
Contact:
SilverCrest Mines Inc.
Fred Cooper
(604) 694-1730 ext. 108
Toll Free: 1-866-691-1730
(604) 694-1761
info@silvercrestmines.com
www.silvercrestmines.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Published at Investorideas.com Newswire
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: SilverCrest Mines has compensated Investorideas.com for the distribution and publishing of this news release (annual news publication 9700) http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

China Social Media and Online Education Company, UMeWorld Limited (OTCQB: UMEWF), Investor Fact Sheet

HONG KONG - July 24, 2013 (Investorideas.com newswire) UMeWorld Limited (OTCQB: UMEWF) is an emerging digital media company focused on facilitating the interaction between people -- "You" and "Me," through its UMeLook and SmartStar digital platforms. Currently, the Company’s main business focus is on the Chinese online video and online education market.
Share Price $0.36
Shares Outstanding 89,036,000
Market Cap. $32.05 Million
52 Week High $0.79
52 Week Low $0.0001
as of July 22, 2013


UMeLook.com is a niche player in the Chinese online video market, wherein the competition is focused on local TV series and, we different ourselves by focusing on foreign videos of less than 10 minutes duration and target affluent Chinese viewers between the age of 18-45 who are interested in foreign information, products and brands. UMeLook.com has also succeeded in entering the Chinese online video market where global players such as YouTube and Dailymotion are blocked and inaccessible in China. UMeLook.com will continue to drive viewership aggressively and in conjunction, are preparing to launch a global e-commerce platform assisting small and medium brands from worldwide sources, to expand into the Chinese market.
SmartStar is a cloud-based, online testing and assessment education platform using a proprietary adaptive learning technology, designed to enhance the performance of Chinese teachers and students. Unlike traditional online courseware, SmartStar provides a concept-level assessment and evaluation of a student's learning progress. It identifies the student's strengths and weaknesses, their proficiency in a given subject area and personalizes the delivery of proprietary educational items according to the student's learning needs. SmartStar is also capable of providing scoring and statistical analysis of exams and evaluations and to provide administration of local and nationally standardized exams. It is ideal for schools and teachers.
The K-12 education system in China is the largest in the world comprising 230 million students and 12 million teachers. Chinese families spend more discretionary income on education than anything other expense, except for housing. The educational landscape in China is highly competitive. Schools dictate entrance requirements for students. This motivates parents to ensure that their children have access to the best educational tools. SmartStar is one such tool.

As prepared by the company, UMeWorld Limited (OTCQB:UMEWF)
Published at Investorideas.com – Big Ideas for Global Investors
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: UMEWF compensates Investorideas.com for news publication and syndication : two thousand per month
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Battelle Team (NxStage Medical(NASDAQ: NXTM) and Aethlon Medical (OTCQB: AEMD) Wins DARPA Contract to Build Medical Device to Treat Sepsis

COLUMBUS, OH - July 24, 2013 (Investorideas.com newswire) At Battelle, supporting America's military personnel is woven into the fabric of its business. In that pursuit, a team consisting of Battelle, NxStage Medical (NASDAQ: NXTM), Inc. and Aethlon Medical (OTCQB: AEMD) has won a contract from the Defense Advanced Research Projects Agency, or DARPA, to develop an innovative, new medical device that may save the lives of soldiers -- and civilians as well -- by treating sepsis.

The problem to be confronted is more severe than is commonly known -- as many as 10 percent of combat wounds result in life threatening infections that ultimately lead to septicemia and/or sepsis. "This device could not only save many of our soldiers' lives, it could be profoundly important in saving thousands of civilian lives each year in the United States alone," said Martin Toomajian, President of Battelle Energy, Health and Environment.
DARPA created the Dialysis-Like Therapeutics (DLT) program to develop a portable device that creates a holistic treatment for sepsis. The device is intended to remove blood from the body, separate harmful "dirty" agents from the blood and return "cleaned" blood to the body in a manner similar to dialysis treatment for kidney failure. DARPA has made significant investments in its DLT effort to date to multiple contractors for the development of key blood purification and diagnostic technologies that could contribute to the ultimate device.
This contract -- which is funded in phases and could be as large as $22.83 million and last as long as four years -- is for leading one of DARPA's DLT System Integration projects. The project calls for Battelle and key subcontractors, NxStage and Aethlon, to design, develop, test and validate an advanced, portable medical device that exhibits the technical innovation for which DARPA projects are known, and to coordinate integration of key technologies developed during the overall DLT program. This funding does not include human clinical trials that may be required prior to military use and/or United States Food and Drug Administration clearance for sepsis-treatment technologies.
Beyond the military need for sepsis therapies, the DLT device may play an important role in saving the lives of civilian patients, as infection leading to sepsis is a significant cause of mortality. When sepsis is complicated by shock, approximately half of patients do not survive for 30 days, even if effective antibiotics are used.
Because of the interdisciplinary nature of the program, it will draw experts from many scientific and engineering segments at Battelle and its development team members. "This program will utilize a highly diverse set of resources, ranging from medical device design to biological testing to meeting the exacting needs of the military-medical environment," said Steve Kelly, President of Battelle National Security. "Battelle is exceptionally qualified, together with the collaboration of NxStage and Aethlon, to bring the necessary diversity of expertise to this complex program."
Battelle will lead a project team focusing on military user needs, systems engineering, integration of DLT technologies and pre-clinical testing. Working closely with Battelle, NxStage will design, develop and ultimately manufacture and distribute the medical device upon regulatory approval. Aethlon is developing and plans to distribute key blood separation component technologies for the DLT system.
"NxStage is pleased to be chosen as part of this team based upon our recognized expertise in developing and commercializing innovative, portable technology for the purification of blood, which includes use of the System One in the military environment," said Jeffrey H. Burbank, Chief Executive Officer of NxStage Medical, Inc. "We are confident that our leadership in device design will lead to a good outcome for this important DARPA project, ultimately benefitting military personnel and civilians alike."
"We are honored to be part of the DLT System Integration team and appreciate the continued opportunity to innovate an effective therapeutic solution to address sepsis," said Aethlon Medical Chairman and CEO Jim Joyce. Aethlon is the previous recipient of a $6.8 million DARPA DLT contract.
About Battelle
Every day, the people of Battelle apply science and technology to solving what matters most. At major technology centers and national laboratories around the world, Battelle conducts research and development, designs and manufactures products, and delivers critical services for government and commercial customers. Headquartered in Columbus, Ohio since its founding in 1929, Battelle serves the national security, health and life sciences, and energy and environmental industries. For more information, visit www.battelle.org.
About NxStage Medical, Inc.
NxStage is a medical device company, headquartered in Lawrence, MA, USA, which develops, manufactures, and markets innovative systems for the treatment of end-stage renal disease (ESRD), and acute kidney failure. The System One™ home hemodialysis device developed by NxStage is the only FDA approved portable hemodialysis machine cleared for home use. For more information on NxStage, or NxStage® products, visit http://www.nxstage.com.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices that provide rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, the Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
For more information contact
Katy Delaney
(614) 424-7208
T.R. Massey
(614) 424-5544
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

Mobile Commerce Stock Alert: Samy Gets New App Redesign for Apple iPhone & Google Android-based Smartphones

SARASOTA, Fla. - July 23, 2013 (www.investorideas.com newswire) via PRWEB - MobileBits, (OTCBB: MBIT), provider of the SAMY(TM) mobile marketing and engagement network, today announced that it has released version 1.5 of its SAMY mobile application suite which includes updates for Apple iOS, availability for popular Android-based smartphones such as Samsung Galaxy, LG, HTC, Sony Ericsson and Motorola, a brand new Amazon Kindle app as well as support for BlackBerry 10 OS phones.
SAMY 1.5 features a redesigned user interface for iOS, as well as an upgrade to the overall application features including faster loading times and responsiveness. It also includes new location functionality support for Android OS, which is now integrated with Google services enabling driving direction integration and seamless location service updates.
A report from Kantar Worldpanel ComTech reveals Android leads smartphone sales and boasts a market dominating 52 percent of the market, but iOS is closing the gap with 41.9 percent of sales. Apple iOS and Android OS represent almost 94 percent of all smartphones sold today.
SAMY is the award-winning, patent-pending direct mobile marketing and engagement network that enables merchants and shopping centers to extend their brands and exclusive promotions to popular smartphones and engage with new and existing customers. SAMY also provides merchants an easy way to quickly integrate important retail touch points including point of sale (POS), gift cards, mobile offers, loyalty systems, social media and more into one single customizable mobile platform.
To get SAMY on your smartphone and start saving today, go to your AppStore and download SAMY or visit samy.com.
About MobileBits Corporation
MobileBits, provider of SAMY, the fast growing 'Mobile Mall' that provides any merchant, retailer or brand with an out-of-the box, ready to deploy, mobile commerce platform to connect with consumers in their local area and help increase sales in the physical store. The solution provides businesses a complete set of tools to connect with, create and manage mobile campaigns, deals, offers, commerce, loyalty and rewards to a subscribed mobile consumer. For more information, visit http://www.mobilebits.com or http://www.samy.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future. There are a number of factors that could cause actual results and developments to differ materially from forecasted results. These risks and uncertainties include our ability to: attract end users; attract advertisers; our ability to successfully implement our current long-term growth strategy; as well as product demand, market competition, fluctuations in advertising payouts, delays in website & application development, technical issues beyond our control, reliance on the various platforms that we build applications on, and risks inherent in our operations. For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available from commercial document retrieval services and at the website maintained by the SEC at http://www.sec.gov.
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2013/7/prweb10942190.htm
Contact:
MobileBits Corporation
JoLynn Blatz
jolynn.blatz@mobilebits.com
941.225.6103
Published at Investorideas.com newswire
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products Or securities. Investorideas.com was compensated one hundred fifty dollars for this single news release.
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Medical Technology Stock Trading Alert: Aethlon Medical (OTCQB: AEMD) Gains 16%

Point Roberts, WA, New York, NY - July 22, 2013 (Investorideas.com newswire) Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, issues a trading alert for Aethlon Medical, Inc. (OTCQB: AEMD), The stock is trading at $0.13, gaining 0.0180 or 16.07% 10:30AM EDT on over 460,000 shares.

Last week Brian Marckx, CFA from Zacks Small Cap Research Issued an updated on the company entitled, “AEMD: Recent Progress Helps De-Risk Aethlon” and increased his price on the stock.
The company also recently reported FDA approval of an Investigational Device Exemption (IDE) that allows the Company to initiate human feasibility studies of the Aethlon Hemopurifier® in the United States. The Hemopurifier ® is a first-in-class medical device that targets the rapid elimination of life-threatening infectious disease and cancer glycopathogens from circulation.
Under the feasibility study protocol, Aethlon will enroll ten end stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy. Successful completion of the feasibility study will set the stage for Aethlon to conduct pivotal studies required for market clearance to treat HCV and potentially other disease conditions.
Full Zacks research news: http://finance.yahoo.com/news/aemd-recent-progress-helps-risk-110000781.html
About Aethlon Medical (OTCQB: AEMD)
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas has been compensated by AEMD for news release distribution and content publishing: three thousand per month effective June 2013 http://www.investorideas.com/About/Disclaimer.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
800-665-0411 or 212-822-8842
Source - www.Investorideas.com

Research Alert: Zacks Small Cap Research Increases Price Target for Aethlon Medical (OTCQB: AEMD)

Point Roberts, WA, New York, NY - July 19, 2013 (Investorideas.com newswire) Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, issues a research alert for Aethlon Medical, Inc. (OTCQB:AEMD), Yesterday Brian Marckx, CFA from Zacks Small Cap Research Issued an updated on the company entitled, “AEMD: Recent Progress Helps De-Risk Aethlon.” In his report he noted, “based on our DCF model AEMD is valued at about $0.15/share."

The company recently reported that the FDA has approved an Investigational Device Exemption (IDE) that allows the Company to initiate human feasibility studies of the Aethlon Hemopurifier® in the United States. The Hemopurifier ® is a first-in-class medical device that targets the rapid elimination of life-threatening infectious disease and cancer glycopathogens from circulation.
Under the feasibility study protocol, Aethlon will enroll ten end stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy. Successful completion of the feasibility study will set the stage for Aethlon to conduct pivotal studies required for market clearance to treat HCV and potentially other disease conditions.
Excerpt from Zacks Small Cap Research, Brian Marckx, CFA:
Since initiating coverage of Aethlon Medical back in March 2012 we listed several risks and concerns, some of which we felt precluded us from assigning a reasonable value on the company. Among the greatest concerns, which we felt had the potential to essentially stop the company in its tracks, were AEMD's outstanding and non-performing debt as well as the real uncertainty of whether FDA would ever green-light the company to run U.S. human trials. And while the debt issue remains an overhang, we feel that the company's success in continuing to raise financing (particularly financing that is subordinate to the debt) and ongoing progress with converting some debt to equity, provides us much more comfort that their still tattered balance sheet can continue to meaningfully improve. We also view, as we explain below, the IDE approval as major positive and while this does not necessarily get the company substantially closer to eventual U.S. commercialization, it removes the most near-term hurdle that AEMD had to clear for that to happen and one that had it not happened, in our opinion could have doomed the company.
For those reasons, we now feel the company's future is less uncertain (or near-term risks are at least meaningfully mitigated) and believe it's now appropriate to use a discounted cash flow model to value the company. We continue to expect somewhat insignificant revenue in the near-to-mid term, largely from the DARPA contract and the subcontract with Battelle. We also think there may be a small revenue contribution from compassionate use of Hemopurifier in India. But, as we noted in our previous updates, a favorable decision by the FDA on the IDE application to begin <_st13a_country-region _w3a_st="on"> U.S. studies would potentially provide some upside to our current financial estimates over the longer term. We have now built a 10-year DCF model through fiscal 2024. Our relatively lofty 15% discount rate is appropriate given our remaining concerns, and risks and hurdles that company will need to clear as well as the potentially lengthy runway until AEMD begins to generate meaningful commercial sales, which we still believe is contingent on launching Hemopurifier in the <_st13a_country-region _w3a_st="on">U.S. Based on our DCF model AEMD is valued at about $0.15/share. We are maintaining our Neutral recommendation. We feel that continued progress in hitting operational and financial milestones would provide additional de-risking and potentially further upside to the value of the company.
Full Zacks research news: http://finance.yahoo.com/news/aemd-recent-progress-helps-risk-110000781.html
About Aethlon Medical (OTCQB: AEMD)
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas has been compensated by AEMD for news release distribution and content publishing: three thousand per month effective June 2013 http://www.investorideas.com/About/Disclaimer.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
800-665-0411 or 212-822-8842
Source - www.Investorideas.com

Medical Technology Stock Breaking News: Aethlon Medical (OTCQB: AEMD) Recent Progress Helps De-Risk Aethlon

July 18, 2013 (Investorideas.com newswire) We have updated our report on Aethlon Medical (OTCBB:AEMD) for their 10-K filing as well as other recent events. See below for access to the full report.

10-K Filed for Fiscal 2013 (ending 3/31/2013)
Aethlon (AEMD) filed their 10-K for the fiscal year ending 3/31/2013 on July 15th. Results (excluding non-cash change in derivative liability expense) remain very much in-line with our estimates. AEMD booked $404k in DARPA contract revenue in Q4 compared to our $380k estimate. Revenue relates to the tenth and eleventh milestones under the DARPA contract (the second and third milestones under the year-2 contract). Subsequent to (in April 2013) the end of fiscal 2013 AEMD booked another $196k related to the twelfth milestone.
These three milestones are (per AEMD's 10-K):
Milestone 2.3.2.1 – Demonstrate the effectiveness of the prototype device in vivo in animals preventing platelet activation or clotting in at least a 2 hour blood pumping experiment at 75 mL/min blood flow. The milestone payment amount was $195,581. Management considers this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts. The prototype device was successfully used in vivo in animals preventing platelet activation or clotting in at least a 2 hour blood pumping experiment at 75 mL/min blood flow. The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.
Milestone M4 – Target capture > 50% in 24 hours for at least 5 targets in blood or blood components. The milestone payment was $208,781. Management considers this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts. We demonstrated that we were able to capture > 50% in 24 hours for at least 5 of the agreed targets in blood or blood components. The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.
Milestone 2.3.2.2 (booked in fiscal Q1 2014) – Formulate initial design based on work from previous phase. Begin to build and test selected instrument design and tubing sets. The milestone payment amount was $195,581. Management considers this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts. We demonstrated that we had begun to build and test selected instrument design and tubing sets. The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.
Through April 2013 AEMD has booked approximately $2.8 million in DARPA revenue and had approximately $790k remaining to invoice under the year 2 contract. As a reminder, DARPA has the option of entering into the remainder of the proposed contract for years three through five, which would pay Aethlon up to an additional $3.2 million, annual payments under which would range between $775k and $1.6 million.
Q4 operating expenses were $1.3 million, just slightly higher than our $1.2 million estimate. Q4 net income and EPS of ($2.8) million and ($0.02) were below our ($1.0) million and ($0.01) due to a non-cash change in derivative liability expense.
Cash
Aethlon exited fiscal 2013 with $125k in cash and equivalents, compared to $108k at the end of the prior quarter (12/31/2012). Subsequent to fiscal year end the company raised an additional $128k from the sale of equity, entered into $400k in loans from directors of the company and collected $404k from the DARPA contract.
Cash used in operations was $522k in Q4 ($2.1 million in 12 months ending 3/31/13), compared to $662k in Q3 and $1.8 million in fiscal 2012. AEMD continues to be successful in raising operating capital, raising over $2.1 million from the sale of common stock in fiscal 2013.
Along with their ongoing ability to continue to raise operating capital, we have been encouraged, from the standpoint of strengthening their financial position and balance sheet, by the success of converting some of their outstanding debt to stock. While a substantial portion of debt remains in default, the company continues to make progress on cleaning up their balance sheet, which we view as meaningful from a de-risking perspective. We reiterate, however, as we have in the past, that Aethlon will need to raise a substantial amount of cash, enter into partnering arrangements or score additional valuable contracts/grants in order to complete the recently announced <_st13a_place _w3a_st="on">U.S. safety study and to be able to maintain operations for the longer-term. Nonetheless, we believe management's recent progress should not be marginalized.
Using DCF To Value AEMD
Since initiating coverage of Aethlon Medical back in March 2012 we listed several risks and concerns, some of which we felt precluded us from assigning a reasonable value on the company. Among the greatest concerns, which we felt had the potential to essentially stop the company in its tracks, were AEMD's outstanding and non-performing debt as well as the real uncertainty of whether FDA would ever green-light the company to run U.S. human trials. And while the debt issue remains an overhang, we feel that the company's success in continuing to raise financing (particularly financing that is subordinate to the debt) and ongoing progress with converting some debt to equity, provides us much more comfort that their still tattered balance sheet can continue to meaningfully improve. We also view, as we explain below, the IDE approval as major positive and while this does not necessarily get the company substantially closer to eventual U.S. commercialization, it removes the most near-term hurdle that AEMD had to clear for that to happen and one that had it not happened, in our opinion could have doomed the company.
For those reasons, we now feel the company's future is less uncertain (or near-term risks are at least meaningfully mitigated) and believe it's now appropriate to use a discounted cash flow model to value the company. We continue to expect somewhat insignificant revenue in the near-to-mid term, largely from the DARPA contract and the subcontract with Battelle. We also think there may be a small revenue contribution from compassionate use of Hemopurifier in India. But, as we noted in our previous updates, a favorable decision by the FDA on the IDE application to begin U.S. studies would potentially provide some upside to our current financial estimates over the longer term. We have now built a 10-year DCF model through fiscal 2024. Our relatively lofty 15% discount rate is appropriate given our remaining concerns, and risks and hurdles that company will need to clear as well as the potentially lengthy runway until AEMD begins to generate meaningful commercial sales, which we still believe is contingent on launching Hemopurifier in the U.S. Based on our DCF model AEMD is valued at about $0.15/share. We are maintaining our Neutral recommendation. We feel that continued progress in hitting operational and financial milestones would provide additional de-risking and potentially further upside to the value of the company.
FDA Grants IDE, Approving Human Study With Hemopurifier
After a years-long quest, Aethlon Medical (AEMD) cleared what we view as a major milestone, announcing in late June that they received IDE approval to initiate a human feasibility study with Hemopurifier. Whether FDA would approve an IDE was an ongoing question in our mind and, given that such an approval would be required as a first step towards potential U.S. commercialization (where we believe the bulk of potential opportunity lies) of the device, was something that could have been highly detrimental to AEMD had FDA denied the IDE request.
As a reminder, in early January 2013 AEMD announced that they submitted an IDE to the FDA seeking approval to commence a 10-patient safety and effectiveness feasibility study of Hemopurifier. Included in the submission was data from the recent and ongoing studies at hospitals in India as well as HCV capture data, the latter which that the FDA had requested at a pre-IDE meeting in 2011. Then in late-March, following response from FDA which included comments and study design considerations, AEMD resubmitted the IDE.
FDA subsequently communicated that they were withholding clearance of the IDE until AEMD addressed the agency's safety concern, namely that the company detail their training and monitoring procedures for heparinization - the anticoagulant used during dialysis and with the Hemopurifier. AEMD noted in early May that they were gathering the requested information and expected to have it submitted to FDA in the coming week (i.e. - by mid-May). Given this recent news of the approved IDE, FDA's safety concerns have clearly been satisfied.
The feasibility study will enroll 10 end stage renal disease patients infected with HCV to demonstrate safety of Hemopurifier therapy. The patients, which must not have received any HCV drug therapy for at least the preceding 30 days, will receive three treatments of standard dialysis in the first week (i.e. - control phase), followed by a total of six dialysis treatments using Hemopurifier over the next two weeks. The rate of adverse events during the control and Hemopurifier treatments will be compared. Viral load changes will also be measured in order to provide an indication of efficacy. AEMD also notes that they may also collect HCV capture data (another efficacy metric with positive results in trials in India and which FDA had previously indicated interest in). AEMD had previously announced that the study is expected to be conducted by the Renal Research Institute, a partnership between Fresenius Medical Care (FMS), a leader in dialysis products and services, and <_st13a_placename _w3a_st="on">Beth Israel Medical Center in NYC. AEMD is now in the process of preparing for the study.
Assuming positive results, the expectation is this will lead to larger U.S. studies to support an eventual FDA approval filing. And while we do not expect U.S. commercialization to be a near-term event, IDE approval to conduct human studies is a huge positive, meaningful hurdle that's now cleared and significantly increases the likelihood of initiation of larger studies to support an eventual FDA filing.
Cancer / Infectious Disease Presentation
Dr. Annette Marleau, AEMD's Director of Tumor Immunology, made a poster presentation titled, "Extracorporeal Exosome Removal: A Therapeutic Strategy to Address an Evolutionary Survival Mechanism Shared by Cancer and Infectious Viral Pathogens" in April at the 2013 International Society of Extracellular Vesicles conference in Boston.
The presentation addressed cancer-secreted exosomes and the role these exosomes play in cancer progression. Aethlon's Hemopurifier directly targets exosomes in infectious diseases and is also being investigated to target cancer-secreted exosomes, something that current cancer drugs fail to sufficiently address. Pre-clinical studies with the Hemopurifier have shown that it can capture exosomes of various cancers including breast, melanoma, ovarian and colorectal.
While cancer currently remains somewhat of a back-burner application for AEMD, the company has been fairly active in pursuing additional research into the role Hemopurifier could play in cancer therapy. Aethlon's focus with cancer had until recently been mostly in the treatment of HER2 breast cancer, although they are also seriously looking at other cancers including melanoma, ovarian, colorectal and lymphoma as they believe their device could also have potential utility with targeting different pathogens and with treating other types of tumors. In particular and based on recent research, melanoma may hold promise for treatment with the Hemopurifier which Aethlon may also pursue in the near future. Furthering AEMD's quest towards application of Hemopurifier in treatment of cancers, in October 2012 the company announced that a U.S. patent was issued to them entitled "Extracorporeal Removal of Microvesicular Particles" which gives AEMD the exclusive right to remove immune suppressive microvesicular particles, which include but are not limited to exosomes from the circulation of treated patients.
Relative to melanoma Aethlon noted in a press release in June 2012 that based on findings from a study led by Cornell University and published in the (online version) journal Nature, that the company may pursue a melanoma treatment study that has been proposed by a (unnamed) U.S. cancer research institute.
The Cornell study found that exosomes released by melanoma cancer cells facilitated the spread of the disease throughout the body and to other organs and bones. There was also a predictive relationship between exosome levels and severity of cancer with late-stage (IV) patients presenting with much greater exosomes levels compared to earlier stage patients. This indicates that removal of exosomes from circulation could reduce progression of the deleterious effects of melanoma to other parts of the body and potentially improve patient outcomes. Aethlon has previously demonstrated in pre-clinical testing that their Hemopurifier can capture exosomes from patients with late stage melanoma.
Melanoma, the incidence of which is growing rapidly, is the most deadly form of skin cancer, accounting for approximately 4% of all skin cancer cases. Melanoma can be lethal, especially if it penetrates the lowest skin layer and enters the lymph system. Statistics show that five-year survivability is as high as 97% if melanoma if diagnosed and treated at its earliest stage (IA) but this drops precipitously as the disease progresses. As such, a device that could effectively treat these late-stage melanoma patients would have massive appeal, not just in the U.S. but worldwide.
As a melanoma study is still in the early proposal stage and Aethlon remains focused on the near-term opportunities with HCV and the DARPA contract, management does not currently have a timeline when a melanoma or other cancer study may commence. This proposed melanoma study could potentially speed Aethlon's cancer program along, although still likely to be more of a back-burner application as Aethlon pursues their near-term endeavors. Nonetheless, we view this as a positive development, potentially offering another opportunity for Aethlon and their Hemopurifier.
In September 2012 AEMD made a presentation at the MD Anderson Cancer Center in Houston entitled, "The extracorporeal removal of tumor-secreted exosomes: An adjunct strategy to reverse immune suppression and inhibit metastases in melanoma". The presentation focused on the potential of the Hemopurifier to be combined with chemo and immunotherapies as a strategy to improve melanoma treatment outcomes.
Battelle Subcontract
In mid-April AEMD announced that they have been selected as a subcontractor by Battelle Memorial Institute under Battelle's $22.8 million systems integrator contract with DARPA related to the sepsis DLT program. The systems integrator is responsible for integrating the various component technologies developed under the DLT program by the various participating organizations, including AEMD. The contract will pay AEMD on a cost (time and materials) plus margin basis so the total that AEMD will eventually bill will not be known until their work is completed. AEMD noted that they began work on this subcontract in early April.
AEMD's Bioterror Program Potentially Revitalized
Another somewhat back-burner application for AEMD's technology has been bioterrorism. Earlier in vivo studies conducted by Aethlon and in conjunction with other organizations, including the Centers for Disease Control and Prevention (CDC), have shown the Hemopurifier was able to rapidly clear viral particles and remove glycoproteins in cell cultures fluids. Pre-clinical studies have shown success with the capture of several Category A (i.e. most serious) pathogens including the Ebola virus, Dengue virus, Lassa virus, West Nile virus, Monkeypox virus, H5N1 Avian flu virus and the H1N1 Swine flu virus.
Aethlon, in collaboration with the United States Army Medical Research Institute for Infectious Diseases (USAMRIID) and other organizations, have worked in the past to validate Hemopurifier for use against Category A threats. Studies have yet to move forward, however - possibly as enrolling for a trial with Ebola infected patients would present serious challenges. As a result, Aethlon's bioterror program had been in somewhat of a holding pattern.
AEMD's bioterror program could potentially be revitalized, however, and sparked by renewed federal funding for bioterror countermeasures (including medical countermeasures) through the Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) of 2013. The CBO estimates that $11 billion will be spent on PAHPRA from 2014 to 2018. Included in the scope of the program is countermeasures against the new strains of bird flu. Given Hemopurifier's success in pre-clinical studies in capturing the H5N1 Avian flu virus and the H1N1 Swine flu virus, AEMD may be in a solid position to pursue any grant funding targeting the new strains of bird flu.
A copy of the full research report can be downloaded here >> Aethlon Medical Report
Please visit SCR.Zacks.com for additional information on our research and coverage universe, and Subscribe to receive our articles and reports emailed directly to you each morning.
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar